Eupraxia Pharmaceuticals Inc. $EPRX Stock Sold by Beutel Goodman & Co Ltd.

Beutel Goodman & Co Ltd. decreased its position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 2.7% in the third quarter, Holdings Channel reports. The institutional investor owned 3,529,124 shares of the company’s stock after selling 98,740 shares during the period. Beutel Goodman & Co Ltd. owned 0.05% of Eupraxia Pharmaceuticals worth $32,289,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth about $25,000. BlackRock Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the 2nd quarter valued at about $40,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Eupraxia Pharmaceuticals by 28.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock valued at $133,000 after purchasing an additional 3,500 shares in the last quarter. AXQ Capital LP increased its stake in shares of Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after purchasing an additional 5,390 shares in the last quarter. Finally, Cibc World Market Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $1,539,000.

Eupraxia Pharmaceuticals Trading Up 7.7%

EPRX stock opened at $7.42 on Tuesday. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals Inc. has a 12-month low of $5.57 and a 12-month high of $9.32. The stock has a market cap of $498.92 million, a price-to-earnings ratio of -7.27 and a beta of 1.04. The business’s 50-day moving average is $7.56 and its 200 day moving average is $7.26.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. On average, sell-side analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.90 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Royal Bank Of Canada began coverage on Eupraxia Pharmaceuticals in a report on Monday. They issued an “outperform” rating and a $14.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 8th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Finally, Wedbush started coverage on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They set an “outperform” rating and a $17.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $17.17.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.